US2014128586A1PendingUtilityA1
Amino-lna, thio-lna and alpha-l-oxy-ln
Est. expiryNov 18, 2022(expired)· nominal 20-yr term from priority
Inventors:Signe M. ChristensenNikolaj Dam MikkelsenMiriam FriedenHenrik Frydenlund HansenTroels KochDaniel Sejer PedersenChristoph RosenbohmCharlotte Albaek ThrueMajken Westergaard
C07H 21/04C07H 19/06C12N 2310/341C07H 21/00C12N 2310/315C07H 19/16C12N 2320/51C12N 2310/3231C07H 21/02C12N 15/113A61K 31/7088C12N 2320/30C12N 15/1137C07H 19/04C12N 2310/344C12N 2310/11C12N 15/111
66
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 - 42 . (canceled)
43 . An LNA nucleoside having the formula:
wherein X is O; R′ and R″ are independently either H or a terminal group; and (CH 2 )n is a methylene substituted with a methyl, or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.